Overview

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Status:
Not yet recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Xiamen University